How Lipfendra, Inclisiran, and New Guidelines Are Changing Cholesterol Management
With more than half of U.S. adults now eligible for statins, the face of cholesterol treatment may be changing with drugs like Lipfendra and Inclisiran. FatCamera · E+/Getty A new analysis found that the twice-yearly cholesterol medication inclisiran reduced LDL cholesterol by 49% more than placebo. The FDA approved Lipfendra, the first oral PCSK9 inhibitor for adults with high LDL cholesterol.…
Recent advancements in cholesterol management are reshaping the landscape of treatment options for high LDL cholesterol. Two noteworthy developments are the FDA approval of Lipfendra, an oral PCSK9 inhibitor, and the implementation of updated cholesterol guidelines. These changes have prompted a reevaluation of who qualifies for statin therapy, potentially affecting millions of adults.
A recent systematic review and meta-analysis revealed that inclisiran, a twice-yearly medication, leads to a significant 49% reduction in LDL cholesterol compared to a placebo. The drug, a synthetic therapy targeting proteins that boost LDL levels, can be taken alone or in combination with statin therapy and diet/exercise for those with hypercholesterolemia. This new option may prove beneficial for individuals struggling with adherence to daily oral medications.
The FDA recently approved Lipfendra, the first oral PCSK9 inhibitor, for adults with high LDL cholesterol. Clinical trials demonstrated its ability to lower LDL cholesterol by 56% to 59%, with the drug available for use alone or alongside statins. While the trials did not examine the drug's impact on heart attack or stroke risk, LDL cholesterol reduction is widely recognized as a valid measure of cardiovascular risk.
Earlier this year, the American Heart Association, American College of Cardiology, and other medical organizations published updated cholesterol guidelines. These recommendations focus on treating high cholesterol at an earlier stage, assessing lipoprotein(a) at least once, and utilizing a newer risk calculator to better predict cardiovascular risk.
The guidelines set lower LDL ("bad") cholesterol targets for high-risk individuals and consider individual risk factors and imaging when determining treatment. According to a study published in JAMA, approximately 56.6% of U.S. adults aged 30 to 79—about 87.5 million people—are now eligible for statin therapy under the revised guidelines, representing a significant increase from previous recommendations.
Written by urgent.news from Healthline News's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
